Division of Palliative Medicine Maine Medical Center Portland ME.
Center for Outcomes Research and Evaluation Maine Medical Center Portland ME.
J Am Heart Assoc. 2020 Sep 15;9(18):e016505. doi: 10.1161/JAHA.120.016505. Epub 2020 Aug 31.
Background Advanced heart failure (AHF) carries a morbidity and mortality that are similar or worse than many advanced cancers. Despite this, there are no accepted quality metrics for end-of-life (EOL) care for patients with AHF. Methods and Results As a first step toward identifying quality measures, we performed a qualitative study with 23 physicians who care for patients with AHF. Individual, in-depth, semistructured interviews explored physicians' perceptions of characteristics of high-quality EOL care and the barriers encountered. Interviews were analyzed using software-assisted line-by-line coding in order to identify emergent themes. Although some elements and barriers of high-quality EOL care for AHF were similar to those described for other diseases, we identified several unique features. We found a competing desire to avoid overly aggressive care at EOL alongside a need to ensure that life-prolonging interventions were exhausted. We also identified several barriers related to identifying EOL including greater prognostic uncertainty, inadequate recognition of AHF as a terminal disease and dependence of symptom control on disease-modifying therapies. Conclusions Our findings support quality metrics that prioritize receipt of goal-concordant care over utilization measures as well as a need for more inclusive payment models that appropriately reflect the dual nature of many AHF therapies.
晚期心力衰竭(AHF)的发病率和死亡率与许多晚期癌症相似甚至更差。尽管如此,对于 AHF 患者的临终关怀,目前还没有公认的质量指标。
作为确定质量指标的第一步,我们对 23 名治疗 AHF 患者的医生进行了一项定性研究。采用个体化、深入的半结构化访谈,探讨了医生对高质量临终关怀特征的看法以及所遇到的障碍。使用软件辅助的逐行编码对访谈进行分析,以确定出现的主题。尽管 AHF 临终关怀的一些要素和障碍与其他疾病描述的相似,但我们也发现了一些独特的特征。我们发现,一方面人们渴望避免在临终时接受过度积极的治疗,另一方面又需要确保延长生命的干预措施已经用尽。我们还发现了一些与确定临终相关的障碍,包括预后不确定性更大、对 AHF 作为终末期疾病的认识不足以及症状控制依赖于疾病修正治疗。
我们的研究结果支持将接受符合目标的治疗作为质量指标,而不是仅仅强调利用率,同时还需要更具包容性的支付模式,以适当反映许多 AHF 治疗的双重性质。